The purpose of this survey is to evaluate the safety (i.e., frequency of adverse events) and
efficacy (i.e., hemostatic effect, rate of rebleeding after confirmation of hemostasis) of
administration of lansoprazole intravenous 30 milligram (mg) (Takepron Intravenous 30 mg) to
a large number of patients in daily medical practice.